Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Revenue (2021 - 2025)

Historic Revenue for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $25000.0.

  • Lyra Therapeutics' Revenue fell 8717.95% to $25000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$934000.0, marking a year-over-year decrease of 16349.42%. This contributed to the annual value of $1.6 million for FY2023, which is 1430.67% up from last year.
  • Latest data reveals that Lyra Therapeutics reported Revenue of $25000.0 as of Q3 2025, which was down 8717.95% from $183000.0 recorded in Q2 2025.
  • In the past 5 years, Lyra Therapeutics' Revenue ranged from a high of $598000.0 in Q2 2024 and a low of -$1.3 million during Q4 2024
  • Over the past 5 years, Lyra Therapeutics' median Revenue value was $271000.0 (recorded in 2021), while the average stood at $211588.2.
  • As far as peak fluctuations go, Lyra Therapeutics' Revenue surged by 246428.57% in 2022, and later plummeted by 100753.42% in 2024.
  • Lyra Therapeutics' Revenue (Quarter) stood at $271000.0 in 2021, then crashed by 95.94% to $11000.0 in 2022, then surged by 1227.27% to $146000.0 in 2023, then tumbled by 1007.53% to -$1.3 million in 2024, then skyrocketed by 101.89% to $25000.0 in 2025.
  • Its Revenue was $25000.0 in Q3 2025, compared to $183000.0 in Q2 2025 and $183000.0 in Q1 2025.